Cosmo Feilding-Mellen sold $154k of ATAI
director at AtaiBeckley Inc.. 39,594 shares at an average of $3.90, traded Jan 2, 2026, filed Jan 6, 2026.
Score components
- +15RoleDirector
- +11Trade size$154k at market
- 0Share of holdings soldSold 0.5% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001140361-26-000415, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 2, 2026 | SOpen-market sale Common Stock | -39,594 | $3.90 | $154k | 7,663,396 | Jan 6, 2026 |
Related signals
Other insiders at AtaiBeckley Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 33Weak | AtaiBeckley Inc. | Robert Hershberg director | $496k 100,000 shares | -50% | |
| 33Weak | AtaiBeckley Inc. | Gerd Kochendoerfer Chief Operating Officer | $250k 50,000 shares | -100% | |
| 27Weak | AtaiBeckley Inc. | Kevin James Craig Chief Medical Officer | $192k 42,579 shares | -83% | |
| 12Weak | AtaiBeckley Inc. | Kevin James Craig Chief Medical Officer | $213k 42,579 shares | -83% | |
| 15Weak | AtaiBeckley Inc. | Kevin James Craig Chief Medical Officer | $355k 100,000 shares | -92% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.